← Eichor
Condition: Recurrent Adenocarcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized C
Phase N/A · 1 location(s) · Mingzhao Xiao · NCT06088134Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic C
NA · 8 location(s) · Aichi Medical University · NCT07235007Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3 · 1 location(s) · Biotech Pharmaceutical Co., Ltd. · NCT05978050Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239CAIX PET/ CT Guided Radiation Therapy in CcRCC.
NA · 1 location(s) · Peking University First Hospital · NCT07540260Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT05444478Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Phase N/A · 2 location(s) · Massachusetts General Hospital · NCT06862856Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150Autologous CAR-T Cells Targeting B7-H3 in PDAC
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06158139Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06454578APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 · 6 location(s) · Mayo Clinic · NCT06205316Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
NA · 1 location(s) · Sun Yat-sen University · NCT06609876IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Tr
Phase 2 · 2 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06654011Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686Title of Manuscript: Development and Internal-external Validation of a Comprehensive Model for Predicting Risk of Post-R
Phase N/A · 1 location(s) · Tian'an Jiang · NCT06577272A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE
Phase N/A · 1 location(s) · Azienda Ospedaliero-Universitaria Careggi · NCT05022914MOv19-BBz CAR T Cells in FRa+ Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07116057An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cel
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06447103Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During o
Phase 1/Phase 2 · 30 location(s) · Merck Sharp & Dohme LLC · NCT07049926SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Phase N/A · 2 location(s) · Peking University First Hospital · NCT06583070Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Phase N/A · 1 location(s) · Tongji Hospital · NCT06653062Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06487481The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT06587425BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P
Phase 2 · 3 location(s) · Mayo Clinic · NCT07226856Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
NA · 1 location(s) · Asan Medical Center · NCT06537193Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC
Phase 2 · 7 location(s) · Advenchen Pharmaceuticals, LLC. · NCT05363280
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.